An autonomous intelligence system is helping seniors stay safe both at home and in care facilities, thanks to a collaboration between University of Alberta computing scientists and software technology company Spxtrm AI.
Many of us use phone apps to manage daily habits such as meal planning, budgeting, and even tracking symptoms of chronic conditions. So what if a web-based app could help people struggling with addiction manage their condition and reduce their risk of overdose?
Canada is in the midst of a crisis. Drug overdose death tolls are rising, and the mounting health care costs of an opioid epidemic have proven that addiction is a multidimensional problem we cannot afford to ignore. Managing the crisis is also affected by public perception. The way we view drug users could significantly affect the way we, as a society, respond to this issue.
Imagine you are adrift, without home or country. You arrive to a new land where you do not speak the language, understand the customs, or know where your next meal is coming from. Thousands of refugees in Canada find themselves in this situation every day.
The scientists who fight the world’s deadliest diseases work hard to keep Ebola and other biohazards isolated from the environment. But because their labs are expensive to build and operate, they’re spread out in cities across the globe, and it can be easy for the experts to become isolated from each other.
As Canada’s fourth largest crop, barley is an important part of the national agricultural landscape. It’s a key component in beer production, which generates 5.8 billion in the economy, and much of it is exported to international markets. Nine out of 10 barley farmers rely on exports for a significant part of their income.
For women who have experienced some form of gender-based violence, accessing help within the health system can be a much more fraught experience — and one student is determined to better understand the many determinants that guide victims’ decisions to seek — or avoid — care.
Canada has the highest rate of inflammatory bowel disease (IBD) in the world. Currently, about 10 to 20 percent of sufferers, including pediatric IBD patients, don’t respond to existing treatments, and that number is expected to increase in the years ahead.